Ian Mortimer

CIK: 0001619961

Transaction Breakdown

Open Market Buys (P)1 (2.5%)

High conviction signal

Open Market Sales (S)22 (55.0%)

Position reduction

Option Exercises (M)12 (30.0%)

Derivative conversions

Awards (A)5 (12.5%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

XENE

Xenon Pharmaceuticals Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (40 total)

XENE
Xenon Pharmaceuticals Inc.
Sep 30, 2026
Purchase(P)
Direct
30K shares at avg. $37.38$1.1M
XENE
Xenon Pharmaceuticals Inc.
Mar 13, 2026
Sale(S)
Direct
7.3K shares at avg. $55.23$404K
XENE
Xenon Pharmaceuticals Inc.
Mar 12, 2026
Exercise(M)
Direct
12.5K shares-
XENE
Xenon Pharmaceuticals Inc.
Mar 10, 2026
Sale(S)
Direct
11.3K shares at avg. $60.11$677K
XENE
Xenon Pharmaceuticals Inc.
Mar 9, 2026
Award(A)
Performance Share Units
Direct
20K shares-
XENE
Xenon Pharmaceuticals Inc.
Mar 9, 2026
Exercise(M)
Direct
75K shares at avg. $8.40$630K
XENE
Xenon Pharmaceuticals Inc.
Mar 9, 2026
Sale(S)
Direct
21.8K shares at avg. $58.81$1.3M
XENE
Xenon Pharmaceuticals Inc.
Mar 9, 2026
Sale(S)
Direct
31.7K shares at avg. $59.88$1.9M
XENE
Xenon Pharmaceuticals Inc.
Mar 9, 2026
Sale(S)
Direct
21.5K shares at avg. $60.49$1.3M
XENE
Xenon Pharmaceuticals Inc.
Mar 9, 2026
Exercise(M)
Direct
25K shares at avg. $3.10$78K
XENE
Xenon Pharmaceuticals Inc.
Mar 9, 2026
Sale(S)
Direct
12.5K shares at avg. $59.50$743K
XENE
Xenon Pharmaceuticals Inc.
Mar 9, 2026
Sale(S)
Direct
10.1K shares at avg. $60.47$609K
XENE
Xenon Pharmaceuticals Inc.
Mar 9, 2026
Sale(S)
Direct
2.4K shares at avg. $61.26$150K
XENE
Xenon Pharmaceuticals Inc.
Mar 9, 2026
Exercise(M)
Direct
105K shares at avg. $4.75$499K
XENE
Xenon Pharmaceuticals Inc.
Mar 9, 2026
Sale(S)
Direct
43.3K shares at avg. $59.26$2.6M
XENE
Xenon Pharmaceuticals Inc.
Mar 9, 2026
Sale(S)
Direct
61.7K shares at avg. $60.08$3.7M
XENE
Xenon Pharmaceuticals Inc.
Mar 9, 2026
Exercise(M)
Direct
65K shares at avg. $9.44$614K
XENE
Xenon Pharmaceuticals Inc.
Mar 9, 2026
Sale(S)
Direct
65K shares at avg. $62.06$4.0M
XENE
Xenon Pharmaceuticals Inc.
Mar 9, 2026
Exercise(M)
Direct
20K shares-
XENE
Xenon Pharmaceuticals Inc.
Jan 9, 2026
Award(A)
Restricted Share Units
Direct
65K shares-
XENE
Xenon Pharmaceuticals Inc.
Jan 9, 2026
Award(A)
Share Option (Right to Buy)
Direct
350K shares-
XENE
Xenon Pharmaceuticals Inc.
Jan 2, 2026
Exercise(M)
Direct
40K shares at avg. $7.49$300K
XENE
Xenon Pharmaceuticals Inc.
Jan 2, 2026
Sale(S)
Direct
2.1K shares at avg. $44.93$93K
XENE
Xenon Pharmaceuticals Inc.
Jan 2, 2026
Sale(S)
Direct
37.9K shares at avg. $44.40$1.7M
XENE
Xenon Pharmaceuticals Inc.
Dec 8, 2025
Sale(S)
Direct
8.8K shares at avg. $45.59$402K

		Type	Shares	Price		Ownership
Sep 30, 2026	XENE Xenon Pharmaceuticals Inc.	Purchase(P)	30,000	$37.38	$1,121,400	Direct
Mar 13, 2026	XENE Xenon Pharmaceuticals Inc.	Sale(S)	7,308	$55.23	$403,584	Direct
Mar 12, 2026	XENE Xenon Pharmaceuticals Inc.	Exercise(M)	12,500	-	$0	Direct
Mar 10, 2026	XENE Xenon Pharmaceuticals Inc.	Sale(S)	11,269	$60.11	$677,357	Direct
Mar 9, 2026	XENE Xenon Pharmaceuticals Inc.	Award(A) Performance Share Units	20,000	-	-	Direct
Mar 9, 2026	XENE Xenon Pharmaceuticals Inc.	Exercise(M)	75,000	$8.40	$630,000	Direct
Mar 9, 2026	XENE Xenon Pharmaceuticals Inc.	Sale(S)	21,791	$58.81	$1,281,529	Direct
Mar 9, 2026	XENE Xenon Pharmaceuticals Inc.	Sale(S)	31,694	$59.88	$1,897,837	Direct
Mar 9, 2026	XENE Xenon Pharmaceuticals Inc.	Sale(S)	21,515	$60.49	$1,301,442	Direct
Mar 9, 2026	XENE Xenon Pharmaceuticals Inc.	Exercise(M)	25,000	$3.10	$77,500	Direct
Mar 9, 2026	XENE Xenon Pharmaceuticals Inc.	Sale(S)	12,479	$59.50	$742,501	Direct
Mar 9, 2026	XENE Xenon Pharmaceuticals Inc.	Sale(S)	10,072	$60.47	$609,054	Direct
Mar 9, 2026	XENE Xenon Pharmaceuticals Inc.	Sale(S)	2,449	$61.26	$150,026	Direct
Mar 9, 2026	XENE Xenon Pharmaceuticals Inc.	Exercise(M)	105,000	$4.75	$498,750	Direct
Mar 9, 2026	XENE Xenon Pharmaceuticals Inc.	Sale(S)	43,348	$59.26	$2,568,802	Direct
Mar 9, 2026	XENE Xenon Pharmaceuticals Inc.	Sale(S)	61,652	$60.08	$3,704,052	Direct
Mar 9, 2026	XENE Xenon Pharmaceuticals Inc.	Exercise(M)	65,000	$9.44	$613,600	Direct
Mar 9, 2026	XENE Xenon Pharmaceuticals Inc.	Sale(S)	65,000	$62.06	$4,033,900	Direct
Mar 9, 2026	XENE Xenon Pharmaceuticals Inc.	Exercise(M)	20,000	-	$0	Direct
Jan 9, 2026	XENE Xenon Pharmaceuticals Inc.	Award(A) Restricted Share Units	65,000	-	-	Direct
Jan 9, 2026	XENE Xenon Pharmaceuticals Inc.	Award(A) Share Option (Right to Buy)	350,000	-	-	Direct
Jan 2, 2026	XENE Xenon Pharmaceuticals Inc.	Exercise(M)	40,000	$7.49	$299,600	Direct
Jan 2, 2026	XENE Xenon Pharmaceuticals Inc.	Sale(S)	2,062	$44.93	$92,646	Direct
Jan 2, 2026	XENE Xenon Pharmaceuticals Inc.	Sale(S)	37,938	$44.40	$1,684,447	Direct
Dec 8, 2025	XENE Xenon Pharmaceuticals Inc.	Sale(S)	8,820	$45.59	$402,104	Direct

1-25 of 40 transactions

About MORTIMER IAN

MORTIMER IAN (SEC CIK 0001619961) files insider reports with the SEC as PRESIDENT & CEO of Xenon Pharmaceuticals Inc. (XENE).

Signal8 holds 10 ownership filings by MORTIMER IAN, all Form 4s, filed between Jan 27, 2025 and Oct 1, 2026. Those filings report 40 transactions, from Jan 23, 2025 to Sep 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on MORTIMER IAN's filings is in BURNABY.

Recent filings by MORTIMER IAN

Sep 30, 2026: Open-market purchase of XENE shares (Form 4, code P).
Mar 13, 2026: Open-market sale of XENE shares (Form 4, code S).
Mar 12, 2026: Option exercise of XENE shares (Form 4, code M).
Mar 10, 2026: Open-market sale of XENE shares (Form 4, code S).
Mar 9, 2026: Grant or award of XENE derivative securities (Form 4, code A).

Other insiders filing for Xenon Pharmaceuticals Inc. (XENE)

Kelly Thomas Patrick, Chief Financial Officer
Svoronos Dawn, Director
GANNON STEVEN, Director
PATOU GARY, Director
Cannon Gillian, Director
Machado Patrick, Director

How to read Form 4 transaction codes